CME and CMLE credits are not available for this webinar.
Description:
Dr. Godley will describe our current understanding of the genes and types of deleterious DNA variants that confer an increased risk for the development of myeloid malignancies. She will discuss which patients are likely to harbor such DNA mutations and comprehensive approaches for making the diagnosis. She will also describe how to use molecular profiling of malignant cells to prioritize patients for appropriate germline genetic testing. Finally, she will describe the importance of identifying germline predisposition alleles to optimize the care of patients undergoing allogeneic hematopoietic stem cell transplantation.
Learning Objectives:
- Discuss the number of genes in which deleterious variants confer increased risk for the development of myeloid malignancies.
- Describe how frequently germline mutations are identified in patients with myeloid malignancies.
- Identify patients with germline predisposition
 |
 |
|---|---|
| Speaker: Lucy A. Godley, MD, PhD The University of Chicago Medicine Chicago, IL |
Moderator: Nathan Montgomery, MD, PhD T&E Committee Member University of North Carolina Chapel Hill, NC |
Duration: 1 hr
Level of Instruction: Basic
Date Recorded: March 9, 2021
Planned and coordinated by the Training and Education Committee
Continuing Education Credit Information
CME and CMLE credits are not available for this webinar.
Note: Members of AMP can access this webinar at no cost. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
